Surgical Endoscopy

, Volume 31, Issue 10, pp 4025–4033 | Cite as

Fully covered stents are similar to semi-covered stents with regard to migration in palliative treatment of malignant strictures of the esophagus and gastric cardia: results of a randomized controlled trial

  • Jan PerssonEmail author
  • Ulrika Smedh
  • Åse Johnsson
  • Bo Ohlin
  • Magnus Sundbom
  • Magnus Nilsson
  • Lars Lundell
  • Berit Sund
  • Erik Johnsson
Open Access



Stent migration is a significant clinical problem in palliation of malignant strictures in the esophagus and gastro-esophageal junction (GEJ). We have compared a newer design of a fully-covered stent to a widely used semi-covered stent using migration >20 mm as the primary outcome variable. Effects on dysphagia, quality of life (QoL) and re-intervention frequency were also investigated.


Patients with dysphagia due to non-curable esophagus/GEJ cancer were randomized to receive either a more recent design of a fully-covered stent (n = 48) or a conventional semi-covered stent (n = 47). Chest x-ray, dysphagia and QoL were studied at baseline, one week, four weeks and three months thereafter.


There were no significant differences either in stent migration distance or in the migration frequency. Stent migration during the total study period occurred in 37.2 % in the semi-covered group compared to 20.0 % for the fully-covered group. Dysphagia was measured with Watson and Ogilvie scores and with the dysphagia module in the QoL scale (QLQ-OG25). On average, there was a tendency to better dysphagia relief for the fully-covered design as scored with the two latter dysphagia instruments (p= 0.081 and p= 0.067) at three months and towards more re-interventions in the semi-covered group (p= 0.083).


In spite of its somewhat lower intrinsic radial force, the fully-covered stent was comparable to the conventional semi-covered stent with regard to stent migration. The data further suggest a potential benefit of the fully-covered stent in improving dysphagia in patients with longer life expectancy.


Stent Esophagus cancer Palliation Dysphagia Stent migration 

The incidence of cancers of the esophagus and gastro-esophageal junction (GEJ) is rising in the Western world [1]. The majority of patients are not eligible for curative treatment due to either an advanced tumor stage or a poor general condition [2, 3]. A very important goal is thus to provide optimized palliative care and to maintain or improve quality of life (QoL). Dysphagia is the most important symptom to relieve, since it affects QoL most negatively [3, 4]. In recent years endoscopically placed self-expandable metallic stents (SEMS) have become a well-documented, effective and widely used palliative treatment for dysphagia, in particular among patients with a life expectancy of less than 3 months [4, 5, 6, 7].

The first commercially available SEMS in the 1990s were uncovered and were associated with a re-intervention rate of up to 30–50%, most commonly due to stent obstruction secondary to tumor or inflammatory tissue in-growth [8, 9]. A variety of different SEMS designs equipped with a plastic lining covering the exterior surface of the stent were subsequently developed to prevent this complication [10]. Unfortunately, whereas the smooth lining of the first generation of covered stents helped to prevent tumor in-growth, those SEMS adhered less well to the esophageal wall. A common and acknowledged disadvantage of fully covered SEMS (fcSEMS) is therefore a high risk (20–39%) for stent dysfunction due to dislocation [11, 12, 13, 14, 15] leading to recurrent or insufficient relief of dysphagia. Semi-covered stents (scSEMS), i.e., covered in the mid portion but with bare mesh endings were developed; these cause less migration-related events although re-obstruction in the uncovered endings may still occur [11, 16, 17]. Despite these limitations scSEMS are commonly used throughout the world. When this study was launched, the scSEMS were the most widely used stents for palliation of cancers of the esophagus and cardia in Sweden, in particular the Ultraflex stent, which therefore was chosen to this study. In recent years, newer designs of fcSEMS modified to reduce the risk of migration have been developed. The fcSEMS used in this study (Wallflex®) differs from earlier generations of fcSEMS designs in several aspects. It has its silicone lining on the interior luminal side of the stent, which leaves the rough surface of the braided stent mesh facing the mucosa. These modifications, together with a different shape of the flare at the endings, are in theory thought to reduce stent migration. Another important factor to consider when studying stent migration is the inborn radial force of the stent. The fcSEMS Wallflex® has a slightly lower radial force compared to the well-established scSEMS Ultraflex® [18], which theoretically could entail a higher risk for migration. Whether the Wallflex® fcSEMS is comparable to the conventional Ultraflex® scSEMS with regard to migration is not yet known.

Previous studies addressing the advantages or limitations of different stent designs in palliation of cancers of the esophagus and cardia have focused on parameters such as QoL, dysphagia relief or need for endoscopic re-interventions due to perceived symptoms as the main outcome measures. However, there is little evidence available concerning the degree of actual stent migration with regard to stent designs. To our knowledge, earlier investigations have consistently shown higher migration rates of fcSEMS regardless of the design [11, 12, 13, 14, 15]. In this study, we therefore tested the hypothesis that the most widely used conventional scSEMS (Ultraflex®) is associated with less stent migration compared to a more modern fcSEMS design (Wallflex®). The primary endpoint of this prospective, randomized study was to compare these stent designs with regard to migration over time using direct measurements in conventional chest X-ray images. The need for re-interventions, effects on dysphagia and QoL, technical failures and survival were used as secondary endpoints.



Between 2011 and 2014, 95 patients with incurable cancer in the esophagus or the GEJ were asked to participate in this prospective randomized study. The patients were recruited from four university hospitals and two district hospitals. The demographic background characteristics of the groups are shown in Table 1. Before the endoscopy, the patients were randomized to receive either an fcSEMS or a scSEMS through a web-based computer-aided system (DynaReg Generic system). By minimization, the groups were stratified between a distal tumor margin of <3 cm, or >3 cm from the GEJ in order to avoid dissimilarities between the groups with regard to the level of the stricture.

Table 1

Background characteristics of the patients included



(n = 47)


(n = 48)

p value

Age year median (min–max)

72.2 (48.2–91.0)

71.2 (56.8–91.0)


Gender (n = female)

11 (23.4%)

13 (27.1%)


Distal margin from cardia <3 cm (n = yes)

33 (70.2%)

35 (72.9%)


Tumor length (cm) median (min–max)

6.0 (1.0–18.0)

6.0 (1.0–14.0)


Tumor type (n = adenocarcinoma)

32 (34.8%)

35 (38.0%)


Metastatic disease (n = yes)

25 (53.2%)

29 (60.4%)


Dilatation during stent procedure

2 (4.2%)

0 (0.0%)


Two-tailed Mann–Whitney U test1 or Pearson Chi-Square test2 was used for data evaluation. p < 0.05 was considered significant

The inclusion criteria were as follows: (1) Biopsy-verified squamous cell carcinoma or adenocarcinoma in the esophagus or the GEJ where stent-treatment is applicable; (2) Age >18 years; (3) swallowing difficulties with a severity of dysphagia of 2–4 according to Ogilvie [19]; (4) Curative treatment not possible; (5) Written informed consent obtained from the patient.

The exclusion criteria were as follows: (1) Other concurrent malignancy that might impact the life span and/or QoL of the patient; (2) Inability to understand or complete the written questionnaire; (3) Need for a stent with the upper margin less than 2 cm from the upper esophageal sphincter; (4) Need of more than one stent to bridge the tumor.


The patients were randomized to receive either a scSEMS (Ultraflex® Esophageal NG Stent System Boston Scientific) or an fcSEMS (Wallflex® fully covered Esophageal stent Boston Scientific). The patients were not informed about which stent they received. The Ultraflex® stent consists of a knitted nickel-titanium alloy (Nitinol) wire tube and has a polyurethane layer, which covers the midsection of the stent extending to within 1.5 cm of either end of the stent (Fig. 1). The stent used in this study had a proximal flare of 23 mm and an inner body diameter of 18 mm. It was available in three lengths: 100, 120, and 150 mm. The Wallflex® stent is made of a multiple-wired mesh of Nitinol and has a full silicone internal covering with progressive step-flared ends (Fig. 1). The body diameter of the stent used was 18 mm, and the flare diameters were 25 mm proximally, and 23 mm distally. This stent was available in three lengths: 103, 123, and 153 mm. All available stent lengths were used in both groups.

Fig. 1

Photograph depicting the stents that were examined in this study with the proximal endings to the left. A The semi-covered Ultraflex® stent; B the fully covered Wallflex® stent

The vast majority of patients undergoing the endoscopic procedure were treated under conscious sedation with midazolam, and alfentanil or pethidine in addition. The upper and when possible also the lower margin of the tumor was marked with a metal clip. If it was impossible to pass the tumor with the endoscope, the length of the obstruction was determined by the radiological findings or by the use of an “on the table” conventional contrast X-ray. Under fluoroscopic X-ray guidance, a guide-wire was passed down to the stomach. When the endoscope had been removed, the stent was inserted over the wire and positioned in relation to the clips. The length of the stent was chosen according to the length of the stricture, and the stent was placed with at least a 2 cm proximal and distal overlap to the upper and lower margins of the tumor. In cases where the stent was positioned with its distal end below the cardia, the distal overlap was aimed at 1 cm. Dilatation was not done routinely to be able to pass the tumor with the endoscope. However, if there were difficulties passing the stricture with the introducer of the stent, a dilatation was performed up to a maximum of 12 mm. Technical failure was defined as inability to place a stent due to technical problems during the initial procedure, or any other event on day 0 that made further participation impossible. Immediately after stent placement, its position was documented with a postero-anterior and lateral chest X-ray. The majority of the patients were examined in the standing position. The patients received additional written and oral information after receiving the stent. These instructions included advice on diet and ingesting only liquid nutrients for the first 3 days after the procedure.


The follow-up was scheduled at 1 week, 4 weeks, and 3 months after the procedure. A chest X-ray was performed on each occasion and the patients filled in the dysphagia and QoL questionnaires. An independent secondary survey of the patient’s medical records at the treating hospital was done after a patient’s death to ensure that any stent-related events and re-interventions had been recorded.


Migration was evaluated by measurements on conventional frontal and lateral chest X-rays by an experienced consultant thoracic radiologist. The stent position was measured on the lateral projection in relation to thoracic structures such as the thoracic vertebrae and the aortic arch. All images were stored and analyzed on the same work station (Advantage Workstation VolumeShare 5 (AW 4.6), GE Healthcare, Waukesha, WI, U.S.A. with Multisync LCD 1990SXI NEC monitors) to minimize any procedure-related differences. It was decided that a stent displacement of >20 mm would be defined as a stent migration. This value was chosen in order to avoid over-interpretation of stent movements mainly due to two reasons; first, some foreshortening of a stent due to its expansion occurs and second, since differences in the level of inspiration might affect the location of the reference anatomical structures within the thoracic cavity. Another rationale was that movements less than 20 mm might not be of clinical significance, since each stent was routinely placed with a 20 mm overlap.

Total dislocation was defined as no stent being visible in the esophagus at X-ray or at endoscopy. The total dislocations were included as a stent migration >20 mm event at the subsequent follow-up and were also evaluated separately.

Re-interventions the indication for re-interventions was patient complaints of sudden or progressive inability to swallow regardless of X-ray findings.

Dysphagia was investigated with two well-known instruments, the Watson dysphagia score [20, 21] and the Ogilvie score [19, 22], as well as with a symptom-oriented quality of life instrument that has a module that captures information regarding swallowing difficulties (QLQ-OG25) [23].

Health-related quality of life (QoL) was measured with validated instruments originating from the European Organization for Research and Treatment of Cancer (EORTC), which has a generic instrument that measures global QoL in patients with cancer (QLQ-C30) [24] and a more symptom-specific instrument that is developed for cancer in the esophagus and stomach (QLQ-OG25) [23]. These are well known, validated instruments with the added benefit of having normal reference values for the healthy population [25, 26].


A sample size of 43 patients in each group was calculated based on an estimate [11, 12, 13, 14, 15] that the expected rate of migration in the conventional scSEMS group was 10% and in the group with fcSEMS 35%, whereupon a corresponding difference could be detected with a power of 80% and a significance level of 95%, (p < 0.05). The SPSS statistical program was applied for data analysis. The point prevalence of data was compared using parametric or non-parametric tests where appropriate. A p value of less than 0.05 was considered statistically significant.


This study was performed according to the Declaration of Helsinki and the Ethical Review Act. The study protocol was approved by the Ethical Review Board Authority in Stockholm (protocol 2009/3:7). Written informed consent was obtained from each participant before inclusion in the trial. The trial is registered in the (NCT 02166320).


Ninety-five patients were included, and 86 patients were available for the initial analysis of the primary outcome variable at 1 week. Because of the nature of this aggressive disease, the number of patients in each group diminished for every scheduled follow-up (Fig. 2). At the scheduled follow-up at 1 week, 15 out of 95 randomized patients had left the study, which means that 80 patients were available for the initial analysis of the secondary variables (2 were dead; 7 had had technical failure; 6 stents had migrated, 3 in each group, to an extent that re-intervention was necessary) (Fig. 2). In 2 patients in the fcSEMS group and 3 patients in the scSEMS group, it was impossible to pass the tumor with the guide-wire. Two additional patients were excluded on day 0 (1 scSEMS patient suffered a perforation requiring surgery and 1 fcSEMS patient did not get the allocated stent). These patients were thus denoted as technical failures. There were no differences in demographic background characteristics between the two groups (Table 1).

Fig. 2

Flow chart showing numbers of patients included in each arm for evaluation of the primary variable, stent migration. Technical failures were defined as either impossibility to place a stent, or any other event that occurred on the day of inclusion that made further evaluation impossible. New/re-adjusted stent was defined as stent migration or dislocation to such an extent that the patient needed a new stent or a re-adjustment of the original one

Stent migration

Over a period of 3 months, 6 out of 45 patients (13.3%) in the fcSEMS group and 11 out of 43 (25.6%) of the patients in the scSEMS group experienced stent migration. During the total survival span of the patients, stent migration occurred in 9 out of 45 (20.0%) of the patients in the fcSEMS group compared to 16 out of 43 (37.2%) of the patients in the scSEMS group, a difference that was not significant (Table 2). In addition, there was no significant difference between the groups at any time point with regard to the migration distance (Table 2). An interesting observation was that stent migration occurred not only in the distal direction but in the oral direction as well, although less frequently (Table 2). In the scSEMS group, 2 patients experienced total stent dislocation at 1 week. At 4 weeks, no patients, and at 3 months, 1 patient, experienced total dislocation in this group. The corresponding figures in the fcSEMS group were 1, ,1, and 0.

Table 2

Stent migration > 20 mm, migration distance in millimeters and numbers of endoscopic re-interventions




p value

Stent migration >20 mm number of cases

 At 1 week




 At 1 month




 At 3 months




 Total numbers at 3 months

11 (25.6%)

6 (13.3%)


 Total number during survival

16 (37.2%)

9 (20.0%)


Migration distance in millimeters

 1 week median (min–max)

2.0 (−20 to 70)

0.0 (−30 to 144)


 1 month median (min–max)

5.5 (−39 to 50)

2.5 (−16 to 91)


 3 months median (min–max)

10.5 (−11 to 42)

0.0 (−7 to 33)


 Proximal migration at one week (n = yes)

8 (24.2%)

13 (36.1%)


Numbers of endoscopic re-interventions

 1 week

6 (13.9%)

5 (11.6%)


 1 month

5 (15.6%)

2 (6.7%)


 3 months

4 (25.0%)

1 (8.3%)


 Total interventions at 3 months

15 (34.9%)

8 (18.6%)


Measured at 1 week, 4 weeks, and 3 months after stent placement. Migration in proximal direction is denoted as negative values. The accumulated numbers at 3 months and during the subjects’ life span are also shown

Pearson Chi-Square test1 or two-tailed Mann–Whitney U test2 was used for data evaluation. p < 0.05 was considered significant


Dysphagia measured with three different instruments displayed similar outcomes. There was a significant reduction of dysphagia for both groups. The data derived with the Ogilvie score and with the dysphagia module (QLQ-OG25) are suggestive of better dysphagia relief for the fcSEMS at 3 months; but these differences did not reach statistical significance (0.081 and 0.067, respectively) (Table 3). Similarly, the differences in the improvement of dysphagia measured with the Watson score seemed in favor of the fcSEMS stent, but this was not statistically substantiated (p = 0.107). There were no differences in any of the scores at the 1 week and 4 week observation points (Table 3).

Table 3

Dysphagia measured with three different scales.




p value

Watson score

 Prestent dysphagia

34.0 (0.0–45.0)

n = 45

36.7 (5.5–45.0)

n = 44


 1 week

30.0 (0.0–44.0)

n = 33

29.5 (0.0–45.0)

n = 30


 1 month

22.5 (4.5–40.0)

n = 27

21.7 (0.0–45.0)

n = 20


 3 months

19.0 (0.0–44.5)

n = 12

4.0 (0.0–40.5)

n = 9



 Prestent dysphagia

2.0 (2.0–4.0)

n = 45

3.0 (2.0–4.0)

n = 45


 1 week

1.5 (0.0–3.0)

n = 33

2.0 (0.0–4.0)

n = 32


 1 month

1.0 (1.0–3.0)

n = 27

1.0 (0.0–3.0)

n = 22


 3 months

1.0 (0.0–4.0)

n = 12

0.0 (0.0–3.0)

n = 9


QLQ-OG25 Dysphagia module

 Prestent dysphagia

66.7 (11.1–100.0)

n = 43

77.8 (11.1–100.0)

n = 43


 1 week

33.3 (0.0–100.0)

n = 33

44.4 (0.0–100.0)

n = 30


 1 month

33.3 (0.0–77.8)

n = 27

44.4 (0.0–77.8)

n = 21


 3 months

22.2 (0.0–100.0)

n = 12

0.0 (0.0–44.4)

n = 8


The two-tailed Mann–Whitney U test was used for data evaluation. p < 0.05 was considered significant. Results are presented as median, range, and n = numbers of patients per group


Overall QoL was measured with EORTC QLQ-C30. Both groups expectedly reported a similarly low global QoL score at randomization. No significant difference in overall QoL between the two stent designs was found during follow-up (Table 4).

Table 4

Overall Quality of life measured with QLQ-C30.




p value

Prestent QoL (QLQ-C30) median (min–max)

41.7 (0.0–91.7)

33.3 (0.00–83.3)


1 week median (min–max)

41.7 (0.0–83.3)

25.0 (0.0–66.7)


1 month median (min–max)

41.7 (0.0–100.0)

33.3 (0.0–66.7)


3 months median (min–max)

62.5 (8.3–83.3)

41.7 (0.0–75.0)


Two-tailed Mann–Whitney U test was used for data evaluation. p < 0.05 was considered significant. Higher value means better perceived QoL. Quite low values were found initially. A random sample of Swedish adults in the same age group has a mean value of 77.5 (SD 22.0)


Kaplan–Meier analysis with the log-rank test showed no significant differences in survival between the groups (p = 0.53).


There were 15 (scSEMS) vs. 8 (fcSEMS) interventions in total over the studied 3 months, where it had been deemed necessary to perform a new endoscopy due to the patient’s complaints or symptoms. Again a tendency toward a lesser need for re-interventions was seen in the fcSEMS group (p = 0.083) (Table 2). The re-interventions in the scSEMS group included the following: 1 patient with a stent dislocation that needed repositioning; 2 patients who needed a new stent due to complete dislocation; 5 patients with well-placed stents and no endoscopy findings that could explain the patient’s complaints; 2 patients with tumor in-growth and 5 patients with food impaction. Corresponding numbers in the fcSEMS group were: 3; 3; 2; 0, and 0, respectively.


There was only one serious complication. A patient in the scSEMS group experienced a perforation at stent insertion on day 0 and received emergency surgery. Other complications that were minor included bleeding, reflux, and pain with no differences between the groups.


For patients with inability to swallow due to an advanced malignancy of the esophagus and GEJ, it is of critical importance to treat the dysphagia and alleviate symptoms. From a patient perspective, it is of great importance that such treatment is safe and effective, and has few side effects, thus minimizing additional interventions. Stent placement has the benefits of providing a well-documented and rapid onset of the effect and is often accessible close to the patient since it can be performed at most local endoscopy units. One challenge is of course to choose an optimal stent type that carries a minimal risk for stent migration and other complications.

In this prospective, randomized study, we aimed to establish whether modifications of an fcSEMS aimed at maintaining its positioning could be sufficient to reduce its tendency to migrate, a phenomenon that often causes symptoms and necessitates re-interventions. Given that earlier studies have consistently shown that fcSEMS are more likely to dislocate than scSEMS [11, 12, 13, 14, 15], we hypothesized that this would still be the case despite of the novel design modifications undertaken to prevent such migration. We found however no difference between the two stent models with regard to the actual distance of migration or the migration frequency. It would appear, then, that the novel design modifications of the fcSEMS, i.e., a flare in both ends with a modified shape and the lining located at the interior side leaving bare mesh on the exterior stent surface, are indeed effective in reducing fully covered stents’ tendency to migrate. Interestingly, this was in spite of the somewhat lower radial force the Wallflex® fcSEMS exhibits compared to the conventional Ultraflex® scSEMS used here. The finding that the need for endoscopic re-interventions was, if anything, lower in the fcSEMS group, further supports the comparable patency of the fcSEMS vs. the scSEMS. Our findings are also consistent with a previous study on malignant strictures in which the safety and efficacy of the fully covered Wallflex® stent were investigated [27]. In that study, however, individual-based effects before and after stent placement were compared with historical data, and no randomized control arm was included [27]. Regardless of these limitations, the inserting of a fcSEMS reduced the risk of recurrent dysphagia due to dislocation, and improved dysphagia scores similar to our findings (Table 3) as well as to earlier descriptive studies on scSEMS [11, 16, 17].

In contrast to earlier investigations [8, 9, 11, 12, 13, 15, 16, 17, 27, 28, 29, 30], we applied a unique but simple method to objectively evaluate stent migration. We used chest X-rays, which allows objective measures of the actual stent position to be taken directly, permitting quantification of any possible changes during the follow-up. It may be argued that small movements of the SEMS may be of marginal clinical importance, and that perceived symptoms and re-interventions rather than direct objective measures of migration distance should therefore be the preferred primary outcome variable. Although it is of vital importance to take into consideration subjective symptoms in clinical palliative care, it is well known that patients with advanced cancer of the esophagus and GEJ do experience a variety of symptoms in general, which may change from day to day [31, 32, 33]. As it was evident in the present study, these symptoms are not necessarily always related to stent migration or dislocation. Thus, if re-interventions decided solely by symptoms are used as the main study outcome variable and as a proxy for migration, it is possible that study patients risk having to undergo some unnecessary invasive endoscopic investigations. Stents as such can also cause symptoms even when they remain in the correct position [14], and conversely movements of the stents may well be missed unless the patient experiences symptom aggravation. Using direct X-ray aided measurements in the studies of stent migration, the location of the stent may be determined more objectively and without burdening the patients with additional invasive procedures unless needed.

In addition to investigating stent migration and allowing for comparisons to be made with earlier studies in which symptoms were used as the main outcome variables, we evaluated dysphagia, QoL, re-interventions, technical failures, and survival as secondary variables. As expected, individual dysphagia scores were improved in response to SEMS placement at all time points. We even noted a tendency toward less dysphagia in the fcSEMS group at 3 months as assessed with the Ogilvie scale and the QLQ-OG25 scale (Table 3). This may suggest that the fcSEMS could be advantageous in providing dysphagia relief in patients with a longer life expectancy. It is difficult to firmly interpret such a potential effect; a limitation of this study is of course that the number of remaining evaluable patients was notably very small in both groups at 3 months, due to the aggressive nature of the cancer disease. In addition, the study was powered with regard to the primary variable, and at a group level, no significant difference between the specific stent designs was detected at any time point with regard to reported dysphagia (Table 4). This latter result notwithstanding, our results motivate a future clinical trial comparing these stent designs powered for measuring dysphagia as the primary outcome variable.

Concerning overall QoL, the scores are concordant to what has previously been reported for corresponding patient groups [3, 34]. We noted that QoL in fact seemed to be unchanged or slightly reduced the first week after SEMS treatment (Table 4). This observation is consistent with earlier studies by Shensi et al. and Madhusudhan et al. [35, 36] suggesting that a stent may cause some initial symptoms that can be negatively perceived such as reflux and pain [14]. Over time, there was an improvement in overall QoL at three months for both stent types, but with no differences between the groups.

In conclusion, this randomized controlled trial shows that the fcSEMS used in this study does not migrate more compared to the conventional scSEMS and indicates that it is at least similar to the conventional scSEMS with regard to migration frequency and distance. Whether newer fcSEMS may have an advantage in providing better dysphagia relief in patients with longer survival expectancy needs to be established.



We are grateful to Dr. Ingemar Bohlin Örebro University Hospital, Örebro, Sweden, and Dr. Farshad Frozanpor Södersjukhuset, Stockholm, Sweden, who helped with the inclusion of patients. We also thank photographer Mr. Lennart Wiman for providing the photograph in Fig. 1. This study was supported by the Gothenburg Medical Society GLS-590761, the Assar Gabrielsson’s Fund, Sweden and ALF-LUA via the Department of Surgery, Sahlgrenska University Hospital.

Compliance with ethical standards


Boston Scientific kindly provided financial support for three study group meetings, but had no influence on study design, data acquisition, data evaluation or interpretation, or the manuscript. Jan Persson, Ulrika Smedh, Åse Johnsson, Bo Ohlin, Magnus Sundbom, Magnus Nilsson, Lars Lundell, Berit Sunde, and Erik Johnsson have no other conflicts of interest to declare.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi: 10.3322/caac.20107 CrossRefPubMedGoogle Scholar
  2. 2.
    Tentzeris V, Lake B, Cherian T, Milligan J, Sigurdsson A (2011) Poor awareness of symptoms of oesophageal cancer. Interact Cardiovasc Thorac Surg 12(1):32–34. doi: 10.1510/icvts.2010.247213 CrossRefPubMedGoogle Scholar
  3. 3.
    Diamantis G, Scarpa M, Bocus P, Realdon S, Castoro C, Ancona E, Battaglia G (2011) Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J Gastroenterol 17(2):144–150. doi: 10.3748/wjg.v17.i2.144 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, Lundell L, Ruth M (2005) Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 18(3):131–139. doi: 10.1111/j.1442-2050.2005.00467.x CrossRefPubMedGoogle Scholar
  5. 5.
    Allum WH, Griffin SM, Watson A, Colin-Jones D (2002) Guidelines for the management of oesophageal and gastric cancer. Gut 50(Suppl 5):v1–v23CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Homs MY, Kuipers EJ, Siersema PD (2005) Palliative therapy. J Surg Oncol 92(3):246–256. doi: 10.1002/jso.20366 CrossRefPubMedGoogle Scholar
  7. 7.
    Siersema PD (2008) Treatment options for esophageal strictures. Nat Clin Pract Gastroenterol Hepatol 5(3):142–152. doi: 10.1038/ncpgasthep1053 CrossRefPubMedGoogle Scholar
  8. 8.
    Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N (1993) A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 329(18):1302–1307. doi: 10.1056/nejm199310283291803 CrossRefPubMedGoogle Scholar
  9. 9.
    Vakil N, Morris AI, Marcon N, Segalin A, Peracchia A, Bethge N, Zuccaro G, Bosco JJ, Jones WF (2001) A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 96(6):1791–1796. doi: 10.1111/j.1572-0241.2001.03923.x CrossRefPubMedGoogle Scholar
  10. 10.
    Hirdes MM, Vleggaar FP, Siersema PD (2011) Stent placement for esophageal strictures: an update. Expert Rev Med Devices 8(6):733–755. doi: 10.1586/erd.11.44 CrossRefPubMedGoogle Scholar
  11. 11.
    Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, van Lanschot JJ, Wijrdeman HK, Mulder CJ, Reinders JG, Boot H, Aleman BM, Kuipers EJ, Siersema PD (2004) Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 364(9444):1497–1504. doi: 10.1016/s0140-6736(04)17272-3 CrossRefPubMedGoogle Scholar
  12. 12.
    Uitdehaag MJ, van Hooft JE, Verschuur EM, Repici A, Steyerberg EW, Fockens P, Kuipers EJ, Siersema PD (2009) A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc 70(6):1082–1089. doi: 10.1016/j.gie.2009.05.032 CrossRefPubMedGoogle Scholar
  13. 13.
    Wagh MS, Forsmark CE, Chauhan S, Draganov PV (2012) Efficacy and safety of a fully covered esophageal stent: a prospective study. Gastrointest Endosc 75(3):678–682. doi: 10.1016/j.gie.2011.10.006 CrossRefPubMedGoogle Scholar
  14. 14.
    Siddiqui AA, Sarkar A, Beltz S, Lewis J, Loren D, Kowalski T, Fang J, Hilden K, Adler DG (2012) Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy. Gastrointest Endosc 76(1):44–51. doi: 10.1016/j.gie.2012.02.036 CrossRefPubMedGoogle Scholar
  15. 15.
    Eloubeidi MA, Lopes TL (2009) Novel removable internally fully covered self-expanding metal esophageal stent: feasibility, technique of removal, and tissue response in humans. Am J Gastroenterol 104(6):1374–1381. doi: 10.1038/ajg.2009.133 CrossRefPubMedGoogle Scholar
  16. 16.
    Verschuur EM, Repici A, Kuipers EJ, Steyerberg EW, Siersema PD (2008) New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol 103(2):304–312. doi: 10.1111/j.1572-0241.2007.01542.x CrossRefPubMedGoogle Scholar
  17. 17.
    van Boeckel PG, Siersema PD, Sturgess R, Dwyer L, Raijman I, Hirdes MM, Vleggaar FP (2010) A new partially covered metal stent for palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc 72(6):1269–1273. doi: 10.1016/j.gie.2010.07.040 CrossRefPubMedGoogle Scholar
  18. 18.
    Hirdes MM, Vleggaar FP, de Beule M, Siersema PD (2013) In vitro evaluation of the radial and axial force of self-expanding esophageal stents. Endoscopy 45(12):997–1005. doi: 10.1055/s-0033-1344985 CrossRefPubMedGoogle Scholar
  19. 19.
    Ogilvie AL, Dronfield MW, Ferguson R, Atkinson M (1982) Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 23(12):1060–1067CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dakkak M, Bennett JR (1992) A new dysphagia score with objective validation. J Clin Gastroenterol 14(2):99–100CrossRefPubMedGoogle Scholar
  21. 21.
    Watson DI, Pike GK, Baigrie RJ, Mathew G, Devitt PG, Britten-Jones R, Jamieson GG (1997) Prospective double-blind randomized trial of laparoscopic Nissen fundoplication with division and without division of short gastric vessels. Ann Surg 226(5):642–652CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mellow MH, Pinkas H (1985) Endoscopic laser therapy for malignancies affecting the esophagus and gastroesophageal junction. Analysis of technical and functional efficacy. Arch Intern Med 145(8):1443–1446CrossRefPubMedGoogle Scholar
  23. 23.
    Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM (2007) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer (Oxf Engl 1990) 43(14):2066–2073. doi: 10.1016/j.ejca.2007.07.005 CrossRefGoogle Scholar
  24. 24.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMedGoogle Scholar
  25. 25.
    Derogar M, van der Schaaf M, Lagergren P (2012) Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol 51(1):10–16. doi: 10.3109/0284186x.2011.614636 CrossRefPubMedGoogle Scholar
  26. 26.
    van der Schaaf M, Derogar M, Lagergren P (2012) Reference values of oesophago-gastric symptoms (EORTC QLQ-OG25) in a population-based setting. Eur J Cancer (Oxf Engl 1990) 48(11):1602–1607. doi: 10.1016/j.ejca.2011.10.026 CrossRefGoogle Scholar
  27. 27.
    Repici A, Jovani M, Hassan C, Solito B, Di Mitri R, Buffoli F, Macri G, Fregonese D, Cennamo V, De Bellis M, Anderloni A, Siersema PD (2014) Management of inoperable malignant oesophageal strictures with fully covered WallFlex((R)) stent: a multicentre prospective study. Digest Liver Dis 46(12):1093–1098. doi: 10.1016/j.dld.2014.08.037 CrossRefGoogle Scholar
  28. 28.
    Bethge N, Vakil N (2001) A prospective trial of a new self-expanding plastic stent for malignant esophageal obstruction. Am J Gastroenterol 96(5):1350–1354. doi: 10.1111/j.1572-0241.2001.03925.x CrossRefPubMedGoogle Scholar
  29. 29.
    Blomberg J, Wenger U, Lagergren J, Arnelo U, Agustsson T, Johnsson E, Toth E, Lagergren P (2010) Antireflux stent versus conventional stent in the palliation of distal esophageal cancer. A randomized, multicenter clinical trial. Scand J Gastroenterol 45(2):208–216. doi: 10.3109/00365520903443860 CrossRefPubMedGoogle Scholar
  30. 30.
    Uitdehaag MJ, Siersema PD, Spaander MC, Vleggaar FP, Verschuur EM, Steyerberg EW, Kuipers EJ (2010) A new fully covered stent with antimigration properties for the palliation of malignant dysphagia: a prospective cohort study. Gastrointest Endosc 71(3):600–605. doi: 10.1016/j.gie.2009.09.023 CrossRefPubMedGoogle Scholar
  31. 31.
    Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM (2000) Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190(5):562–572 discussion 572–563 CrossRefPubMedGoogle Scholar
  32. 32.
    Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349(23):2241–2252. doi: 10.1056/NEJMra035010 CrossRefPubMedGoogle Scholar
  33. 33.
    Layke JC, Lopez PP (2006) Esophageal cancer: a review and update. Am Fam Physician 73(12):2187–2194PubMedGoogle Scholar
  34. 34.
    Straatman J, Joosten PJ, Terwee CB, Cuesta MA, Jansma EP, van der Peet DL (2015) Systematic review of patient-reported outcome measures in the surgical treatment of patients with esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / ISDE. doi: 10.1111/dote.12405 Google Scholar
  35. 35.
    Shenfine J, McNamee P, Steen N, Bond J, Griffin SM (2005) A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess (Winch Engl) 9(5):1–121Google Scholar
  36. 36.
    Madhusudhan C, Saluja SS, Pal S, Ahuja V, Saran P, Dash NR, Sahni P, Chattopadhyay TK (2009) Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life. Dis Esophagus 22(4):331–336. doi: 10.1111/j.1442-2050.2008.00906.x CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Jan Persson
    • 1
    Email author
  • Ulrika Smedh
    • 1
  • Åse Johnsson
    • 2
  • Bo Ohlin
    • 3
  • Magnus Sundbom
    • 4
  • Magnus Nilsson
    • 5
  • Lars Lundell
    • 5
  • Berit Sund
    • 5
  • Erik Johnsson
    • 1
  1. 1.Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University HospitalSahlgrenska Academy at the University of GothenburgGothenburgSweden
  2. 2.Department of Radiology, Institute of Clinical Sciences, Sahlgrenska University HospitalSahlgrenska Academy at the University of GothenburgGothenburgSweden
  3. 3.Department of SurgeryBlekinge HospitalKarlskronaSweden
  4. 4.Department of Surgical SciencesUppsala UniversityUppsalaSweden
  5. 5.Division of Surgery, CLINTEC, Department of Surgical GastroenterologyKarolinska Institute at Karolinska University HospitalStockholmSweden

Personalised recommendations